Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
AKRO 10.21.2024
Drug:EFX efruxifermin
Diseases:metabolic dysfunction-associated steatohepatitis (MASH)
Date of Upcoming Event:2024-11-15
Name of Upcoming Event:75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024
About Gravity Analytica
Recent News
- 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
- 01.13.2025 - Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
- 01.07.2025 - Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Recent Filings
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and two late-breaking poster presentations at the 75thAnnual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®2024 taking place from November 15-19, 2024, in San Diego. The presentations will highlight findings from the 96-week Phase 2b HARMONY study evaluating the efficacy and safety of lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3), along with insights from an analysis using AI and digital-based pathology.
Details for the presentations are as follows:
Title:Efruxifermin Significantly Improved Liver Fibrosis at Week 96 in the HARMONY Study Across Subgroups and Improvements Were Associated With Changes in Biomarkers
Presenter:Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Date/Time:Sunday, November 17, 2024, from 2:00 PM – 2:15 PM PST
Publication Number:158
Oral Session:MASLD and MASH – New Therapies
Title:Efruxifermin significantly reduced proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study
Presenter:Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Date/Time:Monday, November 18, 2024, from 8:00 AM – 5:00 PM PST
Publication Number:5021
Session:Late Breaking Posters
Title:AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study
Presenter:Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Date/Time:Monday, November 18, 2024, from 8:00 AM – 5:00 PM PST
Publication Number:5047
Session:Late Breaking Posters
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONYHistology, SYNCHRONYReal-World, and SYNCHRONYOutcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4) in which patients have been treated for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us atakerotx.comand follow us onLinkedInandXfor more information.
Investor Contact:Christina TartagliaPrecision AQ212.362.1200christina.tartaglia@precisionaq.com
Media Contact:Peg RusconiDeerfield GroupPeg.rusconi@deerfieldgroup.com
